{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:06:11Z","timestamp":1792249571304,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with epithelial ovarian cancer have the best overall survival when maximal surgical effort is accomplished. However, despite numerous technological advances, surgery still relies primarily on white-light reflectance and the surgeon\u2019s vision. As such, micrometastases are usually missed and most patients clinically classified as a complete responder eventually recur and succumb to the disease. Our objective is to develop optical enhancers which can aid in the visualization of ovarian cancer micrometastasis. To this end we developed a nanoparticle (NP) platform, which is specifically targeted to the tumor microenvironment. Targeting is achieved by coating FDA-approved PLGA-PEG NP with the peptide sequence RGD, which binds with high affinity to \u03b1V\u03b23 integrins present in both the tumor-associated neovasculature and on the surface of ovarian cancer cells. Administration of the NP platform carrying fluorescent dyes to mice bearing intraperitoneal ovarian cancer allowed visualization of tumor-associated vasculature and its contrast against normal blood vessels. More importantly, we demonstrate the visualization of intraperitoneal ovarian cancer micrometastasis as small as 100\u2009\u03bcm with optimal resolution. Finally, we demonstrate that the fluorescent dye cargo was able to penetrate intra-tumorally. Such modality could be used to allow microscopic surgical debulking to assure maximal surgical effort.<\/jats:p>","DOI":"10.1038\/srep40989","type":"journal-article","created":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T12:16:04Z","timestamp":1485346564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Novel approach for the detection of intraperitoneal micrometastasis using an ovarian cancer mouse model"],"prefix":"10.1038","volume":"7","author":[{"given":"Ayesha B.","family":"Alvero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eydis","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia J.","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cardenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Pitruzzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Arin","family":"Silasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"BFsrep40989_CR1","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.12968\/bjon.2013.22.Sup17.S23","volume":"22","author":"C Rooth","year":"2013","unstructured":"Rooth, C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 22, S23\u201330 (2013).","journal-title":"Br J Nurs"},{"key":"BFsrep40989_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.6004\/jnccn.2008.0058","volume":"6","author":"RJ Morgan Jr.","year":"2008","unstructured":"Morgan, R. J. Jr. et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6, 766\u2013794 (2008).","journal-title":"J Natl Compr Canc Netw"},{"key":"BFsrep40989_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123nrc1123 [pii]","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502\u2013516, doi: 10.1038\/nrc1123nrc1123 [pii] (2003).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep40989_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4161\/cc.23406","volume":"12","author":"I Chefetz","year":"2013","unstructured":"Chefetz, I. et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle 12, 511\u2013521, doi: 10.4161\/cc.23406 (2013).","journal-title":"Cell Cycle"},{"key":"BFsrep40989_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/cam4.115","volume":"2","author":"V Craveiro","year":"2013","unstructured":"Craveiro, V. et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2, 751\u2013762, doi: 10.1002\/cam4.115 (2013).","journal-title":"Cancer Med"},{"key":"BFsrep40989_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/3510216735102167 [pii]","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105\u2013111, doi: 10.1038\/3510216735102167 [pii] (2001).","journal-title":"Nature"},{"key":"BFsrep40989_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/IGC.0000000000000066","volume":"24","author":"NJ Al Mutairi","year":"2014","unstructured":"Al Mutairi, N. J. & Le, T. Does modality of adjuvant chemotherapy after interval surgical debulking matter in epithelial ovarian cancer?: An exploratory analysis. Int J Gynecol Cancer 24, 461\u2013467, doi: 10.1097\/IGC.0000000000000066 (2014).","journal-title":"Int J Gynecol Cancer"},{"key":"BFsrep40989_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11912-001-0037-0","volume":"3","author":"CS Chu","year":"2001","unstructured":"Chu, C. S. & Rubin, S. C. Second-look laparotomy for epithelial ovarian cancer: a reappraisal. Curr Oncol Rep 3, 11\u201318 (2001).","journal-title":"Curr Oncol Rep"},{"key":"BFsrep40989_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/1098-2388(200007\/08)19:1<54::AID-SSU9>3.0.CO;2-9","volume":"19","author":"EA Sijmons","year":"2000","unstructured":"Sijmons, E. A. & Heintz, A. P. Second-look and second surgery: second chance or second best? Semin Surg Oncol 19, 54\u201361 (2000).","journal-title":"Semin Surg Oncol"},{"key":"BFsrep40989_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/B978-0-12-411638-2.00005-7","volume":"124","author":"SB Mondal","year":"2014","unstructured":"Mondal, S. B. et al. Real-time fluorescence image-guided oncologic surgery. Adv Cancer Res 124, 171\u2013211, doi: 10.1016\/B978-0-12-411638-2.00005-7 (2014).","journal-title":"Adv Cancer Res"},{"key":"BFsrep40989_CR11","doi-asserted-by":"crossref","unstructured":"Lewellen, K. A., Metzinger, M. N., Liu, Y. & Stack, M. S. Quantitation of Intra-peritoneal Ovarian Cancer Metastasis. Journal of visualized experiments: JoVE, doi: 10.3791\/53316 (2016).","DOI":"10.3791\/53316"},{"key":"BFsrep40989_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijpharm.2005.11.003","volume":"308","author":"V Saxena","year":"2006","unstructured":"Saxena, V., Sadoqi, M. & Shao, J. Polymeric nanoparticulate delivery system for Indocyanine green: biodistribution in healthy mice. Int J Pharm 308, 200\u2013204, doi: 10.1016\/j.ijpharm.2005.11.003 (2006).","journal-title":"Int J Pharm"},{"key":"BFsrep40989_CR13","first-page":"45","volume":"62","author":"I Rivolta","year":"2011","unstructured":"Rivolta, I. et al. Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles. J Physiol Pharmacol 62, 45\u201353 (2011).","journal-title":"J Physiol Pharmacol"},{"key":"BFsrep40989_CR14","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nnano.2015.330","volume":"11","author":"S Schottler","year":"2016","unstructured":"Schottler, S. et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat Nanotechnol 11, 372\u2013377, doi: 10.1038\/nnano.2015.330 (2016).","journal-title":"Nat Nanotechnol"},{"key":"BFsrep40989_CR15","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/sj.onc.1206347","volume":"22","author":"S Cruet-Hennequart","year":"2003","unstructured":"Cruet-Hennequart, S. et al. alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22, 1688\u20131702, doi: 10.1038\/sj.onc.1206347 (2003).","journal-title":"Oncogene"},{"key":"BFsrep40989_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1593\/neo.08740","volume":"10","author":"CN Landen","year":"2008","unstructured":"Landen, C. N. et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10, 1259\u20131267 (2008).","journal-title":"Neoplasia"},{"key":"BFsrep40989_CR17","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1515\/BC.2003.120","volume":"384","author":"S Hapke","year":"2003","unstructured":"Hapke, S. et al. Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3\/Vitronectin interaction. Biol Chem 384, 1073\u20131083, doi: 10.1515\/BC.2003.120 (2003).","journal-title":"Biol Chem"},{"key":"BFsrep40989_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0046-8177(97)90033-2","volume":"28","author":"H Liapis","year":"1997","unstructured":"Liapis, H., Adler, L. M., Wick, M. R. & Rader, J. S. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 28, 443\u2013449 (1997).","journal-title":"Hum Pathol"},{"key":"BFsrep40989_CR19","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1021\/mp3002733","volume":"9","author":"F Danhier","year":"2012","unstructured":"Danhier, F., Le Breton, A. & Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 9, 2961\u20132973, doi: 10.1021\/mp3002733 (2012).","journal-title":"Mol Pharm"},{"key":"BFsrep40989_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1022983000355","volume":"20","author":"B Felding-Habermann","year":"2003","unstructured":"Felding-Habermann, B. Integrin adhesion receptors in tumor metastasis. Clinical & experimental metastasis 20, 203\u2013213 (2003).","journal-title":"Clinical & experimental metastasis"},{"key":"BFsrep40989_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1586\/erm.09.15","volume":"9","author":"JM Lu","year":"2009","unstructured":"Lu, J. M. et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 9, 325\u2013341, doi: 10.1586\/erm.09.15 (2009).","journal-title":"Expert Rev Mol Diagn"},{"key":"BFsrep40989_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10549-010-1130-6","volume":"128","author":"JS Mieog","year":"2011","unstructured":"Mieog, J. S. et al. Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Res Treat 128, 679\u2013689, doi: 10.1007\/s10549-010-1130-6 (2011).","journal-title":"Breast Cancer Res Treat"},{"key":"BFsrep40989_CR23","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-16-0005","volume":"15","author":"AB Alvero","year":"2016","unstructured":"Alvero, A. B. et al. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo . Mol Cancer Ther 15, 1279\u20131290, doi: 10.1158\/1535-7163.MCT-16-0005 (2016).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep40989_CR24","doi-asserted-by":"crossref","unstructured":"Craveiro, V., Yang-Hartwich, Y., Holmberg, J., Sumi, N., Pizzonia, J., Griffin, B., Gill, S., Silasi, D., Azodi, M., Rutherford, T., Alvero, A. B. & Mor, G. Phenotypic Modifications in Ovarian Cancer Stem Cells Following Paclitaxel Treatment. Cancer Medicine (2013).","DOI":"10.1002\/cam4.165"},{"key":"BFsrep40989_CR25","doi-asserted-by":"publisher","first-page":"940585","DOI":"10.1155\/2012\/940585","volume":"2012","author":"JT Alander","year":"2012","unstructured":"Alander, J. T. et al. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging 2012, 940585, doi: 10.1155\/2012\/940585 (2012).","journal-title":"Int J Biomed Imaging"},{"key":"BFsrep40989_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/0265204031000150876","volume":"20","author":"JG Eley","year":"2003","unstructured":"Eley, J. G. & Tirumalasetty, P. P. Release characteristics of polymethacrylate nanospheres containing coumarin-6. J Microencapsul 20, 653\u2013659, doi: 10.1080\/0265204031000150876 (2003).","journal-title":"J Microencapsul"},{"key":"BFsrep40989_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3978\/j.issn.2223-4292.2012.09.04","volume":"2","author":"SL Gibbs","year":"2012","unstructured":"Gibbs, S. L. Near infrared fluorescence for image-guided surgery. Quant Imaging Med Surg 2, 177\u2013187, doi: 10.3978\/j.issn.2223-4292.2012.09.04 (2012).","journal-title":"Quant Imaging Med Surg"},{"key":"BFsrep40989_CR28","doi-asserted-by":"publisher","first-page":"e0129766","DOI":"10.1371\/journal.pone.0129766","volume":"10","author":"QR Tummers","year":"2015","unstructured":"Tummers, Q. R. et al. The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer. PloS one 10, e0129766, doi: 10.1371\/journal.pone.0129766 (2015).","journal-title":"PloS one"},{"key":"BFsrep40989_CR29","doi-asserted-by":"publisher","first-page":"6463","DOI":"10.1038\/ncomms7463","volume":"6","author":"D Asanuma","year":"2015","unstructured":"Asanuma, D. et al. Sensitive beta-galactosidase-targeting fluorescence probe for visualizing small peritoneal metastatic tumours in vivo . Nat Commun 6, 6463, doi: 10.1038\/ncomms7463 (2015).","journal-title":"Nat Commun"},{"key":"BFsrep40989_CR30","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1021\/mp3002733","volume":"9","author":"F Danhier","year":"2012","unstructured":"Danhier, F., Le Breton, A. & Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Molecular pharmaceutics 9, 2961\u20132973, doi: 10.1021\/mp3002733 (2012).","journal-title":"Molecular pharmaceutics"},{"key":"BFsrep40989_CR31","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/00006676-200208000-00021","volume":"25","author":"R Hosotani","year":"2002","unstructured":"Hosotani, R. et al. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 25, e30\u201335 (2002).","journal-title":"Pancreas"},{"key":"BFsrep40989_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1593\/neo.04538","volume":"7","author":"X Chen","year":"2005","unstructured":"Chen, X. et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7, 271\u2013279, doi: 10.1593\/neo.04538 (2005).","journal-title":"Neoplasia"},{"key":"BFsrep40989_CR33","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/modpathol.3880447","volume":"14","author":"A Vonlaufen","year":"2001","unstructured":"Vonlaufen, A. et al. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 14, 1126\u20131132, doi: 10.1038\/modpathol.3880447 (2001).","journal-title":"Mod Pathol"},{"key":"BFsrep40989_CR34","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao, Y. et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67, 5821\u20135830, doi: 10.1158\/0008-5472.CAN-06-4499 (2007).","journal-title":"Cancer Res"},{"key":"BFsrep40989_CR35","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ygyno.2012.12.011","volume":"128","author":"NJ Harlaar","year":"2013","unstructured":"Harlaar, N. J. et al. Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3-)integrin targeted agent. Gynecol Oncol 128, 590\u2013595, doi: 10.1016\/j.ygyno.2012.12.011 (2013).","journal-title":"Gynecol Oncol"},{"key":"BFsrep40989_CR36","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1038\/onc.2015.262","volume":"35","author":"E Shinderman-Maman","year":"2016","unstructured":"Shinderman-Maman, E. et al. The thyroid hormone-alphavbeta3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation. Oncogene 35, 1977\u20131987, doi: 10.1038\/onc.2015.262 (2016).","journal-title":"Oncogene"},{"key":"BFsrep40989_CR37","doi-asserted-by":"publisher","first-page":"915140","DOI":"10.1155\/2012\/915140","volume":"2012","author":"K Sawada","year":"2012","unstructured":"Sawada, K., Ohyagi-Hara, C., Kimura, T. & Morishige, K. Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol 2012, 915140, doi: 10.1155\/2012\/915140 (2012).","journal-title":"J Oncol"},{"key":"BFsrep40989_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/10611860802088630","volume":"16","author":"F Esmaeili","year":"2008","unstructured":"Esmaeili, F. et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 16, 415\u2013423, doi: 10.1080\/10611860802088630 (2008).","journal-title":"J Drug Target"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep40989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40989","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep40989.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:35:06Z","timestamp":1671831306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep40989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,30]]}},"alternative-id":["BFsrep40989"],"URL":"https:\/\/doi.org\/10.1038\/srep40989","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]},"assertion":[{"value":"25 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40989"}}